Medeiros-Domingo Argelia, Bhuiyan Zahurul A, Tester David J, Hofman Nynke, Bikker Hennie, van Tintelen J Peter, Mannens Marcel M A M, Wilde Arthur A M, Ackerman Michael J
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Am Coll Cardiol. 2009 Nov 24;54(22):2065-74. doi: 10.1016/j.jacc.2009.08.022.
This study was undertaken to determine the spectrum and prevalence of mutations in the RYR2-encoded cardiac ryanodine receptor in cases with exertional syncope and normal corrected QT interval (QTc).
Mutations in RYR2 cause type 1 catecholaminergic polymorphic ventricular tachycardia (CPVT1), a cardiac channelopathy with increased propensity for lethal ventricular dysrhythmias. Most RYR2 mutational analyses target 3 canonical domains encoded by <40% of the translated exons. The extent of CPVT1-associated mutations localizing outside of these domains remains unknown as RYR2 has not been examined comprehensively in most patient cohorts.
Mutational analysis of all RYR2 exons was performed using polymerase chain reaction, high-performance liquid chromatography, and deoxyribonucleic acid sequencing on 155 unrelated patients (49% females, 96% Caucasian, age at diagnosis 20 +/- 15 years, mean QTc 428 +/- 29 ms), with either clinical diagnosis of CPVT (n = 110) or an initial diagnosis of exercise-induced long QT syndrome but with QTc <480 ms and a subsequent negative long QT syndrome genetic test (n = 45).
Sixty-three (34 novel) possible CPVT1-associated mutations, absent in 400 reference alleles, were detected in 73 unrelated patients (47%). Thirteen new mutation-containing exons were identified. Two-thirds of the CPVT1-positive patients had mutations that localized to 1 of 16 exons.
Possible CPVT1 mutations in RYR2 were identified in nearly one-half of this cohort; 45 of the 105 translated exons are now known to host possible mutations. Considering that approximately 65% of CPVT1-positive cases would be discovered by selective analysis of 16 exons, a tiered targeting strategy for CPVT genetic testing should be considered.
本研究旨在确定运动性晕厥且校正QT间期(QTc)正常的病例中,由RYR2编码的心脏雷诺丁受体的突变谱及突变率。
RYR2突变可导致1型儿茶酚胺能多形性室性心动过速(CPVT1),这是一种心脏离子通道病,发生致命性室性心律失常的倾向增加。大多数RYR2突变分析针对的是由不到40%的翻译外显子编码的3个典型结构域。由于在大多数患者队列中尚未对RYR2进行全面检测,这些结构域之外的CPVT1相关突变的范围仍不清楚。
对155名无亲缘关系的患者(49%为女性,96%为白种人,诊断时年龄20±15岁,平均QTc 428±29毫秒)进行所有RYR2外显子的突变分析,这些患者要么临床诊断为CPVT(n = 110),要么最初诊断为运动诱发的长QT综合征但QTc<480毫秒且随后长QT综合征基因检测为阴性(n = 45)。使用聚合酶链反应、高效液相色谱和脱氧核糖核酸测序进行分析。
在73名无亲缘关系的患者(47%)中检测到63个(34个新的)可能与CPVT1相关的突变,在400个参考等位基因中未发现这些突变。鉴定出13个新的含突变外显子。三分之二的CPVT1阳性患者的突变定位于16个外显子中的1个。
在该队列中近一半的患者中鉴定出了RYR2中可能的CPVT1突变;现在已知105个翻译外显子中有45个存在可能的突变。鉴于通过对16个外显子进行选择性分析可发现约65%的CPVT1阳性病例,应考虑采用分层靶向策略进行CPVT基因检测。